A new method based on reverse-phase HPLC combined with photodiode array (PDA) was developed to quantify the release of trans-resveratrol (tRES) from solid lipid nanoparticles (SLN). The mobile phase was composed of 75:0:25 (V/V) water/methanol/acetonitrile at 0-3.5 min, 32.5:30.0:37.5 (V/V) water/methanol/acetonitrile at 3.6-5.8 min, and 75:0:25 (V/V) water/methanol/acetonitrile at 5.9-10 min. The flow rate was set at 1.0 mL/min, and tRES was detected at the wavelength of 306.6 nm. A concentration range of 1-100 µg/mL was used to obtain the linear calibration curve. SLN were produced by ultrasound technique to load 0.1% (wt/wt) of tRES, and the in vitro release of the drug was run in modified Franz diffusion cells. The mean recovery of tRES was found to be 96.84 ± 0.32%. The intra-assay and inter-assay coefficients of variation were less than 5%. The proposed method was applied to in vitro permeability studies, and the Weibull model was found to be the one that best fits the tRES release, which is characterized by a simultaneous lipid chain relaxation and erosion during drug release.
Introduction
Resveratrol (trans-4,3 ,5 -trihydroxystilbene) is a natural compound found in grapes and in many other medicinal plants [1] . Resveratrol acts as phytoalexin protecting the plant against virus infections. The high concentration of this compound in red wine is attributed to its high concentration in the in the skin of red grapes [2] . Resveratrol (C14H12O3) is a whitish color powder with a molecular weight of 228.25 g/mol, its solubility varies from 0.03 g/L in water to 16 g/L in DMSO and 50 g/L in ethanol. Its melting point ranges from 253 to 255 °C, exhibiting a log P of 3.1 [3, 4] . Although poorly water soluble, resveratrol shows high membrane permeability and may be considered as a Class II of the Biopharmaceutics Classification System (BCS) [3, 5] . Besides its glycoside form, resveratrol occurs in the cis-(Z) and trans-(E) structural isomers, which exhibit distinct biological effects [6, 7] . Ultraviolet (UV) radiation induces partial conversion of trans-(E) isomer into cis-(Z), resulting in a mix of the two isomers ( Figure 1 ) [8] . From the perspective of nutraceutical applications [9] [10] [11] [12] [13] [14] [15] [16] [17] , research is being demonstrating that trans-resveratrol (tRES) offers many health benefits e.g., as it: (i) lowers the risk of cardiovascular complications [18, 19] , (ii) protects the human body against retinal ischemia by downregulating matrix metalloproteinase-9 expression by nitric oxide and by upregulating heme oxygenase-1 [20] ; (iii) improves cells sensitivity to insulin, reducing oxidative stress, and activating protein kinase B pathway in type 2 diabetic patients [21] [22] [23] ; (iv) acts as a therapeutic agent for neurodegenerative diseases e.g., in Alzheimer's disease, Parkinson's disease, or multiple sclerosis [24, 25] ; (v) modulates inflammatory arthritis by selectively suppressing key cellular and humoral responses required for disease settling [26] ; (vi) inhibits platelet aggregation and synthesis of thromboxane B2 and hydroxyl heptadecatrienoate (HHT) [27] ; (vii) exhibits antiherpetic activity [28] and (viii) chemopreventive properties [29] .
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Scientific literature describes the encapsulation of tRES in different types of lipid nanoparticles [4, 30, 31] , which have demonstrated to be taken up by cells [32] , and accumulated around nuclei. Guo et al. [33] showed that tRES concentration was greatly increased in the target tissue when tRES-loaded nanoparticles were injected [33] . Moreover, tRES-loaded nanoparticles promoted greater tumor growth inhibition. Jung et al. [34] demonstrated that tRES loaded in PEGylated polymeric nanoparticles based on polylactic acid cores (PEG-PLA, of MW 5000:5000) exhibited in vitro and in vivo antitumor effects such as the dose-dependent reduction of cell viability, the suppression of glucose metabolism, improved animal survival, and reduced tumor volume. Among the several types of nanoparticles, solid lipid nanoparticles (SLN) have been showing high physical stability, biodegradability, and biocompatibility for a set of administration routes [35, 36] , the potential to modify the release kinetics of loaded drugs [37, 38] , as well as potential for crossing the cellular membrane and to accumulate in the perinuclear region without toxic effect [32, 39, 40] .
Methods commonly used for the quantification of resveratrol when loaded in nanoparticles do not promote the separation of the isoforms (trans-and cis-) of the drug. Furthermore, a monograph of tRES in official compendia is not yet available. For this purpose, the validation of a suitable quantitative method for this drug becomes a demand, for which the first step is to identify the critical parameters and to establish the acceptance criteria [41] . For the quantification of tRES, some analytical procedures have already been described, e.g., high-performance liquid chromatography (HPLC) coupled with UV, high-performance thin-layer chromatography (HPTLC), fluorescence and electrochemical detection, liquid chromatography coupled to mass spectrometry, gas chromatography, or capillary electrophoresis [42] .
In this work, we describe a reverse-phase HPLC coupled with photodiode array for the quantification of tRES released from SLN in modified Franz diffusion cells. SLN composed of stearic From the perspective of nutraceutical applications [9] [10] [11] [12] [13] [14] [15] [16] [17] , research is being demonstrating that trans-resveratrol (tRES) offers many health benefits e.g., as it: (i) lowers the risk of cardiovascular complications [18, 19] , (ii) protects the human body against retinal ischemia by downregulating matrix metalloproteinase-9 expression by nitric oxide and by upregulating heme oxygenase-1 [20] ; (iii) improves cells sensitivity to insulin, reducing oxidative stress, and activating protein kinase B pathway in type 2 diabetic patients [21] [22] [23] ; (iv) acts as a therapeutic agent for neurodegenerative diseases e.g., in Alzheimer's disease, Parkinson's disease, or multiple sclerosis [24, 25] ; (v) modulates inflammatory arthritis by selectively suppressing key cellular and humoral responses required for disease settling [26] ; (vi) inhibits platelet aggregation and synthesis of thromboxane B2 and hydroxyl heptadecatrienoate (HHT) [27] ; (vii) exhibits antiherpetic activity [28] and (viii) chemopreventive properties [29] .
In this work, we describe a reverse-phase HPLC coupled with photodiode array for the quantification of tRES released from SLN in modified Franz diffusion cells. SLN composed of stearic acid as solid lipid and poloxamer 407 as surfactant have been produced by ultrasound (US) technique.
The effect of the presence of a co-surfactant (i.e., soy phosphatidylcholine) on the release profile of tRES from SLN was also evaluated and fitted to different mathematical models (Korsmeyer-Peppas, Higuchi, First Order, Weibull and Zero Order kinetics).
Material and Methods

Materials
As standard chemical substance, trans-resveratrol 99%, batch number #030M5216V, from Sigma-Aldrich (Taufkirchen, Germany) was used. Acetonitrile and methanol of HPLC grade were purchased from Fisher Scientifics (Pittsburg, USA) and glacial acetic acid of analytical grade was obtained from Merck GmbH (Darmstadt, Germany).
Chromatographic Parameters
An absorbance spectrum scan was recorded between 280 and 350 nm to determine the wavelength of maximum absorbance of tRES. Detection in the UV range was fixed at 306.6 nm, and the peak area was analyzed automatically. The experiment was conducted by reverse-phase HPLC using the 2996 Waters ® photodiode array detector and the 2695 Waters ® Alliance quaternary pump for 10 min. A Phenomenex (Torrance, CA, USA) RP-C18 Luna column of 250 mm × 4.6 mm I.D. 5 µm was kept at 24 ± 1 • C. Gradient elution was carried out, and the mobile phase was composed of 75:0:25 (V/V) water/methanol/acetonitrile at 0-3.5 min; 32.5:30.0:37.5 (V/V) water/methanol/acetonitrile at 3.6-5.8 min, and 75:0:25 (V/V) water/methanol/acetonitrile at 5.9-10 min. The selected mobile phase promoted a better separation of transand cis-resveratrol without enlarging the chromatogram peak. The flow rate was set at a constant of 1.0 mL/min.
Method Validation
The International Conference on Harmonization (ICH) [43] and National Agency for Sanitary Vigilance Agency (ANVISA) [44] guidelines were followed for the validation of the proposed method. Accuracy, precision, linearity, specificity, limit of detection (LOD), limit of quantification (LOQ), and robustness were the selected analytical parameters for validation.
Accuracy
Accuracy stands for the nearness of the results obtained experimentally in relation to theoretical values. The recovery percentage of known tRES amounts from three different concentrations of tRES solutions (5.0, 50.0, and 100.0 µg/mL) was calculated [44] . According to Brazilian regulations, the results should not exceed 5%.
Precision
The daily (intraday) and day-to-day (interday) precision was analyzed using three consecutive injections of tRES solution at three different concentrations (1.0, 50.0, and 100.0 µg/mL), followed by determination of the average, the standard deviation (SD), and the relative standard deviation (RSD) [44] .
Linearity
Linearity represents a linear relationship between the concentration of the drug and its peak area. Three calibration curves were built with tRES solutions in acetonitrile at different concentrations (1.0-100.0 µg/mL). All solutions were freshly prepared and filtered through a 0.45-µm membrane prior to HPLC injection. The linearity was determined by linear regression analysis [45] .
Specificity
Specificity translates the capacity of the method to discriminate between tRES and the other closely related structures present in the samples, such as lipids and surfactants [46] . Specificity was assessed by analyzing the filtrate of drug-free SLN (10.000 NMWL membranes, Millipore, Billerica, MA, USA) and further comparing the resulting chromatogram with that obtained for 50.0 µg/mL tRES standard sample.
Limit of Detection (LOD) and Limit of Quantification (LOQ)
LOD and LOQ are determined using the standard deviations of the slope and Y-intercept of the obtained calibration curve.
Both LOD and LOQ were calculated applying the following equations [44] :
where SD stands for the standard deviation of the Y-intercept and S stands for the slope of the calibration curve.
Robustness
Robustness is defined as the ability of the method to give the same results upon small changes of the chromatographic experimental conditions, indicating its reliability during normal usage. Robustness was checked, stressing the samples at 25, 30 and 35 • C and changes on flow rate at 0.8, 1.0, and 1.2 mL/min.
Measurement of tRES Stability under UV Exposure
A solution of 50.0 µg/mL trans-resveratrol was prepared and exposed for one hour to a 365 nm UVA light in a Benchtop 2UV Transilluminator (LMS-20, UVP Ltd., AnalytikJena, Jena, Germany), at 0 cm distance from the 16 W light source (on the top of the UV light). Resveratrol isomers were quantified by the validated HPLC method (n = 3).
Production and Characterization of SLN
Blank SLN (tRES-free) and tRES-loaded SLN formulations were prepared using the ultrasound (US) technique, modified after Pimentel-Moral et al. [47] . The developed formulation consisted of 5.0% of stearic acid as solid lipid (Galena, Campinas, SP, Brazil), with or without of 1.2% soy phosphatidylcholine (Epikuron ® 200, Cargill, Hamburg, Germany); and the water phase consisted of 3.5% of poloxamer 407 (Pluronic ® F127, Sigma-Aldrich, St. Louis, MO, USA); 0.18% of methyl paraben (Nipagin ® M, PharmaSpecial, Itapevi, SP, Brazil), and 0.02% of propyl paraben (Nipasol ® M, PharmaSpecial, Itapevi, SP, Brazil) ( Table 1) . The water phase was firstly heated up to 70 • C, and then added to a previously prepared mixture of solid lipid (stearic acid) and soy phosphatidylcholine (Epikuron ® 200) for F2 and F2.RES heated at the same temperature, or to the melted solid lipid in case of F1 and F1.RES, to produce a pre-emulsion. The obtained pre-emulsion was stirred with a 752A-2 magnetic stirrer (Fisatom, São Paulo, SP, Brazil) for 1 min, and heat was kept constant. A sonication probe (Branson Sonifier 250, Branson Ultrasonics Corporation, Frederick, MD, USA) was placed in the pre-emulsion for 20 min, applying a power output of amplitude of 47%. Ice was used to lower the temperature during sonication, because preliminary studies showed that in these conditions, the produced nanoparticles would have a lower mean hydrodynamic diameter and polydispersity index. For tRES-loaded SLN (F1.RES and F2.RES), the drug was added to melted stearic acid prior to sonication of the pre-emulsion. tRES (Resveratrol extract 100%, Galena, Campinas, SP, Brazil) was used in a concentration of 0.1% (wt/wt). All formulations were prepared following the same procedure [48] . After sonication, the formulations were centrifuged for 10 min at 5000 rpm to eventually eliminate the titanium fragments that could be released from the probe tip during sonication [49] . The mean hydrodynamic diameter and polydispersity index were determined by dynamic light scattering (Zetasizer Nano ZS, Malvern Instruments, Malvern UK). Samples were previously diluted with ultra-purified water to suitable concentration and analyzed in triplicate.
Drug Release Data Modeling
In vitro tRES release from SLN formulation was carried out in modified Franz diffusion cells (Microette Plus™, Hanson Research, Chatsworth, CA, USA) with a diffusional surface area of 1.77 cm 2 and volume of acceptor compartment of 7.0 mL. A pre-hydrated membrane of cellulose acetate with 0.45 µm was assembled between the donor and acceptor compartments, and a volume of 300 µL of SLN with 0.1% tRES was placed onto the membrane surface in the donor compartment (6 cells/formulation). The acceptor compartment was filled with an aqueous solution of 2% (V/V) of polysorbate 80 to assure that the sink conditions were met during the release experiments [48] . The acceptor solution was maintained at a temperature of 32 ± 2 • C and constant stirring rate of 300 rpm. At suitable time intervals (5, 15 , and 30 min and 1, 2, 4, 6, 8, 12, 16, 20, and 24 h), a volume of 1.5 mL of each cell was sampled from the acceptor compartment with a previously pre-heated syringe connected with a needle (32 ± 2 • C), followed by the replacement of the medium of same volume with automatic collector system (Auto Multi Fill™, Hanson Research, Chatsworth, CA, USA). Before the quantification of tRES released in the acceptor solution, the sampled volumes were passed through a 0.21 µm syringe filter (Millipore ® , Darmstadt, Germany), followed by HPLC analysis applying the validated conditions described in this work.
Statistical Analysis
For parametric data, ANOVA (analysis of variance) and Tukey test were applied, using Origin 12.5 software. Statistical significance was set at p < 0.05.
Results and Discussion
After 1 h of exposure to UV light of standard solution of tRES, partial transformation of transto cis-resveratrol was observed i.e., 89.87% of trans isomer in solution was converted to cis form. It is expected that loading tRES into SLN would contribute to enhance the stability of the trans-isoform, limiting the risk of conversion into the cis-isoform. The mean recovery of trans-isoform was 96.84 ± 0.32%, whereas for cis-isoform it was 3.18 ± 0.47%. The decrease in the intensity of the chromatographic peak of trans-resveratrol was proportional to the area of new chromatographic peak, corresponding to cis-resveratrol. The cis-resveratrol may also show health benefits, but has lower biological activity [50] . To overcome these shortcomings, our main purpose was to validate a suitable analytical procedure for the quantification of resveratrol that could be used for both isomers. Since conversion occurs from transto cis-, the trans-isomeric form has been selected as the active ingredient to be loaded in SLN. Due to the instability of cis-resveratrol, this isomer is not commercially available.
The identification by high-performance liquid chromatography-diode array detection (HPLC-DAD) of analytes in pharmaceutical formulations was realized by Pragst et al. [51] , and it is based on a combination of retention time and spectral matching in the UV region obtained at diode array. UV spectra generated for trans-resveratrol and cis-resveratrol could be easily differentiated due to the high resolution, accuracy, and sensitivity in the wavelength (200 to 400 nm) [52] .
For a spectrum to be identified, a mathematical comparison with a spectra library is usually carried out, requiring the calculation of a similarity index within the entire spectra range and wavelengths measured allowing the recognition of very small differences (i.e., 181 points of comparison in the range of 200 to 380 nm) [51] .
The distinct retention times of transand cis-resveratrol in the RP-HPLC chromatogram are shown in Figure 2a , and the respective UV absorption spectra recorded in the range of 280-350 nm are displayed in Figure 2b ,c.
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The distinct retention times of trans-and cis-resveratrol in the RP-HPLC chromatogram are shown in Figure 2a , and the respective UV absorption spectra recorded in the range of 280-350 nm are displayed in Figure 2b ,c. The UV absorbance spectrum of trans-resveratrol (Figure 2b) shows a lambda max (λ max) at 306.6 nm, while the UV absorbance spectrum of cis-resveratrol (Figure 2c ) exhibits λ max at 285.2 nm. Similar results have been described in the scientific literature, in which 285 nm and 306 nm of UV absorbance spectra have been reported of cis-and trans-resveratrol, respectively [53, 54] . After UV light exposure, a tRES solution of 50 µg/mL exhibited a proportional decrease of the peak area of trans-resveratrol and an increase of the peak area of cis-resveratrol.
The resolution of chromatographic peak (Rs) is a quantitative measure of the peak width, i.e., it measures the separation of two peaks of different retention times t in the chromatogram. The valley between the peaks should touch the baseline, and for complete resolution of the peak, the ideal value should be Rs ≥1.5 [55] . However, values between 1.2 ≥ Rs ≥ 1.5 are often enough. Our results exhibited an Rs value of 1.2; for validation of the analytical method for the quantification of tRES, the UV detection was fixed at 306.6 nm.
The analytical curves were obtained at 12 concentration levels, each recorded in triplicate. According to RDC 899/2003 [44] , the acceptable linearity is when the linear correlation coefficients (R 2 ) are greater than 0.99. The mean R 2 obtained in the experimental measure was 0.9998, demonstrating that linearity proved to be acceptable for the quantification of tRES. The obtained linear regression equation was y = 400628x − 144146, where y stands for the peak area (AU), and x stands for the tRES concentration (µg/mL). The UV absorbance spectrum of trans-resveratrol ( Figure 2b) shows a lambda max (λ max) at 306.6 nm, while the UV absorbance spectrum of cis-resveratrol ( Figure 2c ) exhibits λ max at 285.2 nm. Similar results have been described in the scientific literature, in which 285 nm and 306 nm of UV absorbance spectra have been reported of cisand trans-resveratrol, respectively [53, 54] . After UV light exposure, a tRES solution of 50 µg/mL exhibited a proportional decrease of the peak area of trans-resveratrol and an increase of the peak area of cis-resveratrol.
The analytical curves were obtained at 12 concentration levels, each recorded in triplicate. According to RDC 899/2003 [44] , the acceptable linearity is when the linear correlation coefficients (R 2 ) are greater than 0.99. The mean R 2 obtained in the experimental measure was 0.9998, demonstrating that linearity proved to be acceptable for the quantification of tRES. The obtained linear regression equation was y = 400,628x − 144,146, where y stands for the peak area (AU), and x stands for the tRES concentration (µg/mL).
Method specificity was analyzed with respect to the risk of interference between the lipids and surfactants composing SLN and their effect in the tRES retention time [46] . The three distinct samples were filtered before analysis by the proposed HPLC method. When comparing the results with a chromatogram of tRES standard solution of 50 µg/mL (Figure 3a,b) , no interferences between the components of SLN could be recorded. As shown in Figure 3a , for all the tested formulations, the filtrate of blank SLN (F1) did not exhibit any peak at the tRES retention time. These results demonstrate the specificity of the proposed HPLC-PDA to identify and to quantify the trans isomeric form (tRES) released from SLN. Method specificity was analyzed with respect to the risk of interference between the lipids and surfactants composing SLN and their effect in the tRES retention time [46] . The three distinct samples were filtered before analysis by the proposed HPLC method. When comparing the results with a chromatogram of tRES standard solution of 50 µg/mL (Figure 3a,b) , no interferences between the components of SLN could be recorded. As shown in Figure 3a , for all the tested formulations, the filtrate of blank SLN (F1) did not exhibit any peak at the tRES retention time. These results demonstrate the specificity of the proposed HPLC-PDA to identify and to quantify the trans isomeric form (tRES) released from SLN. Three different tRES standard solutions, each concentration prepared in triplicate (n = 3) (1.0, 50.0, and 100.0 µg/mL), were analyzed in three consecutive days. The results obtained for the assessment of precision are shown in Table 2 . The obtained results document the acceptable intraday and interday precisions of our method. Three different tRES standard solutions, each concentration prepared in triplicate (n = 3) (1.0, 50.0, and 100.0 µg/mL), were analyzed in three consecutive days. The results obtained for the assessment of precision are shown in Table 2 . Table 2 . Results achieved for the intraday and interday precision of the method and results found for method accuracy. The obtained results document the acceptable intraday and interday precisions of our method. All the data were within the acceptance criteria of RSD lower than 5.0%, which attributes a high degree of agreement between the results when analyzed with the same experimental conditions. The method proved to be accurate, not exceeding ± 10.0% [44] , demonstrating the proximity of experimental results with the real value.
Robustness can be measured by assessing the effect of small fluctuations in the chromatographic experimental conditions on the retention time and obtained RSD value [46] . Robustness was evaluated by analyzing the 50.0 µg/mL tRES standard solution. The results are shown in Table 3 . The standard solution was prepared in triplicate (n = 3). No significant changes in the retention time were observed when flow was changed, and a similar result was shown when varying the temperature. The tested variations were among the values allowed by ANVISA [44] , for which the RSD is ± 5.0%. The method was shown to be robust for the flow but not for the temperature.
The LOD and LOQ obtained in this work were 1.29 µg/mL and 4.29 µg/mL, respectively. The literature reports that the LOD and LOQ depend on various factors such as the method (e.g., spectrophotometric, fluorometric, mass spectrometry) and type/quantity of sample. Neves et al. developed a methodology using chromatographic separation connected to a fluorometric detector [56] . The objective was to detect the concentration of nanomolars between 1 and 229 nmol/L of tRES loaded in lipid nanoparticles to evaluate in vitro intestinal assays, using Caco-2 cell monolayers. The authors showed a successfully quantification and low-cost analysis, enabling the improvement pharmacokinetic studies. In another study, the LOD and LOQ of tRES in polymeric nanoparticles, as recorded by chromatography with photodiode array, were found to be 1.29 µg/mL and 4.29 µg/mL, respectively [57] . While the sensitivity of the method has not been one of the selected parameters for its validation, the recorded LOD and LOQ confirm the capacity of our RP-HPLC-PDA to identify and quantify resveratrol. In addition, our method is easy, of straightforward implementation, and of low cost. Therefore, it has been used for in vitro studies.
Stearic acid has been selected as the solid lipid from the preliminary screening of the solubility of tRES in a set of solid lipids (data not shown), while the surfactant combination has been based on reports from scientific literature [46] . SLN with a mean hydrodynamic diameter of 237.03 ± 1.80 nm (F1.tRES) and 201 ± 2.04 nm (F2.tRES), and a polydispersity index of 0.206 ± 0.012 nm (F1.tRES) and 0.153 ± 0.061 nm (F2.tRES) were obtained by ultrasound technique, and the validated method was applied for the quantification of tRES released from SLN in Franz diffusion cells. The drug release from SLN may occur either by diffusion from the nanoparticles surface or from the lipid matrix, or by erosion [58] . The in vitro release profiles of tRES from SLN are shown in Figure 4 . There was no statistical difference (p < 0.05) in tRES release between F1.tRES and F2.tRES, demonstrating that the addition of soy phosphatidylcholine in the formulation had no influence on the size and tRES release from the developed SLN. The first release of tRES was observed only 1 h after the beginning of the assay. For F1.tRES formulation, about 38.82 ± 2.30 (µg/cm 2 ) of the drug was released after 24 h, while for F2.tRES, about 41.03 ± 4.28 (µg/cm 2 ) of the drug was released within the same time frame.
The tRES release data were adjusted using the mathematical models (zero-order and first-order kinetic, Higuchi, Weibull, and Korsmeyer-Peppas models) determining the linear regression. Table  4 summarizes the regression coefficients (R 2 ) for tRES released from SLN. The criterion for selecting the most appropriate mathematical model was established to be the highest value of R 2 . According to the obtained R 2 values (Table 4 ), the Weibull model was the one that best described the tRES release from SLN, which translates a complex release mechanism, involving simultaneously polymer chain relaxation and erosion during drug release.
Barzegar-Jalali et al. [59] compared 13 mathematical models of kinetic release data of 32 drugs from 106 dispersions published in the literature [60] . The obtained results show that the Weibull model was superior over the other tested models, as it translates the complex release behavior of tRES from nanoparticles. The lipid composition of the formulation is of utmost relevance in the design of the tRES release kinetics from SLN, because the lipid is responsible for the loading of drug in the matrix. We have demonstrated that stearic acid figuring in both formulations (F1.RES and F2.RES) promotes the slow rate of drug release from the developed SLN. However, during the release experiments, the drug is being dissolved, thereby increasing the matrix porosity, which promotes a faster drug release. Research has demonstrated that raising the amount of stearic acid associated with the hydrophilic polymer promotes matrix solubilization increases the matrix porosity and promotes There was no statistical difference (p < 0.05) in tRES release between F1.tRES and F2.tRES, demonstrating that the addition of soy phosphatidylcholine in the formulation had no influence on the size and tRES release from the developed SLN. The first release of tRES was observed only 1 h after the beginning of the assay. For F1.tRES formulation, about 38.82 ± 2.30 (µg/cm 2 ) of the drug was released after 24 h, while for F2.tRES, about 41.03 ± 4.28 (µg/cm 2 ) of the drug was released within the same time frame.
The tRES release data were adjusted using the mathematical models (zero-order and first-order kinetic, Higuchi, Weibull, and Korsmeyer-Peppas models) determining the linear regression. Table 4 summarizes the regression coefficients (R 2 ) for tRES released from SLN. The criterion for selecting the most appropriate mathematical model was established to be the highest value of R 2 . According to the obtained R 2 values (Table 4 ), the Weibull model was the one that best described the tRES release from SLN, which translates a complex release mechanism, involving simultaneously polymer chain relaxation and erosion during drug release.
Barzegar-Jalali et al. [59] compared 13 mathematical models of kinetic release data of 32 drugs from 106 dispersions published in the literature [60] . The obtained results show that the Weibull model was superior over the other tested models, as it translates the complex release behavior of tRES from nanoparticles. The lipid composition of the formulation is of utmost relevance in the design of the tRES release kinetics from SLN, because the lipid is responsible for the loading of drug in the matrix. We have demonstrated that stearic acid figuring in both formulations (F1.RES and F2.RES) promotes the slow rate of drug release from the developed SLN. However, during the release experiments, the drug is being dissolved, thereby increasing the matrix porosity, which promotes a faster drug release. Research has demonstrated that raising the amount of stearic acid associated with the hydrophilic polymer promotes matrix solubilization increases the matrix porosity and promotes a faster drug release [60] . Due to the lipophilic character of SLN, these particles act as absorption enhancers upon oral administration, contributing to improving the bioavailability of the loaded active ingredients [61] [62] [63] [64] . SLN also show great potential for the oral delivery of nutraceutics [47, [65] [66] [67] , which is a research area that is receiving growing attention both from academia and industry [68] [69] [70] [71] . Nutraceuticals bridge the gap from conventional pharmacological therapy, and the use of natural substances able to prevent/delay the onset of long-term pathological conditions. They are placed in a gray area between pharmaceuticals and food, and have been recently named as: "the phytocomplex, if they derive from a food of vegetal origin, and as the pool of the secondary metabolites if they derive from a food of animal origin, concentrated and administered in the more suitable pharmaceutical form" [14, 68] . This study addresses the emerging new branch of "Nanonutraceutical Science" [67, 72] . Nanonutraceutical formulations are being exploited for their efficacy, safety, and effect, and could be another tool in the arsenal of strategies that are helpful in managing health conditions, especially in patients who are not eligible for a conventional pharmacological therapy. Recent examples are the end points reached on the use of milk thistle (Silybum marianum) in liver diseases, and the use of the apple phytocomplex against hypercholesterolemy [9, 73] . The stability of nutraceuticals in new nanoformulations is a recent research area with foreseen important outcomes. SLN can be further processed in foodstuffs to increase their ratio in active ingredients. Together with the chemical protection that SLN may offer, the modified release profile of resveratrol can also be exploited for other administration routes to reduce cytotoxicity, improve cell-stress response, offer photoprotection, and increase drug solubility and antitumor response.
Conclusions
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